Huakang Biomedical Holdings Co (HKSE:08622) Debt-to-Equity : 0.10 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Debt-to-Equity?

Huakang Biomedical Holdings Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$4.33 Mil. Huakang Biomedical Holdings Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1.29 Mil. Huakang Biomedical Holdings Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$55.80 Mil. Huakang Biomedical Holdings Co's debt to equity for the quarter that ended in Dec. 2023 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Huakang Biomedical Holdings Co's Debt-to-Equity or its related term are showing as below:

HKSE:08622' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.1
Current: 0.1

During the past 9 years, the highest Debt-to-Equity Ratio of Huakang Biomedical Holdings Co was 0.10. The lowest was 0.02. And the median was 0.04.

HKSE:08622's Debt-to-Equity is ranked better than
71.43% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:08622: 0.10

Huakang Biomedical Holdings Co Debt-to-Equity Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Debt-to-Equity Chart

Huakang Biomedical Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.04

0.03

0.10

Huakang Biomedical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	N/A	0.04	N/A	0.10

Competitive Comparison of Huakang Biomedical Holdings Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Huakang Biomedical Holdings Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Huakang Biomedical Holdings Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huakang Biomedical Holdings Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Huakang Biomedical Holdings Co's Debt-to-Equity falls into.

Huakang Biomedical Holdings Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Huakang Biomedical Holdings Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.33	+	1.287)	/	55.804
	=	0.10

Huakang Biomedical Holdings Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.33	+	1.287)	/	55.804
	=	0.10

Huakang Biomedical Holdings Co (HKSE:08622) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Huakang Biomedical Holdings Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Huakang Biomedical Holdings Co (HKSE:08622) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN

Website

http://www.szhuakang.com

Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.

Executives

Tgga, Llc	2106 Person having a security interest in shares
Lau Lai Yee	2201 Interest of corporation controlled by you
Kokusai Resources Company Limited	2101 Beneficial owner
Zhang Shuguang	2101 Beneficial owner
Crystal Grant Limited	2101 Beneficial owner
Chang Yim Yang	2401 A concert party to an agreement to buy shares
Ever Charming Inc.	2101 Beneficial owner
Wealthy Pride Investment Limited	2101 Beneficial owner

Huakang Biomedical Holdings Co (HKSE:08622) Headlines

No Headlines